Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Stog

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Anticancer Research|January 9, 2021
Vimentin 3 Expression in Prostate Cancer CellsBarbara KÖditz, Andreas Stog, Heike GÖbel, et al.
Biomedicines|November 27, 2025
Evaluation of Stereopsis Performance, Gaze Direction and Pupil Diameter in Post-COVID Syndrome Using Machine LearningThomas S Knauer, Christian Y Mardin, Jürgen Rech, et al.
Eclinicalmedicine|July 30, 2025
Safety, tolerability and clinical effects of rovunaptabin, also known as BC007 on fatigue and quality of life in patients with Post-COVID syndrome (reCOVer): a prospective, exploratory, placebo-controlled, double-blind, randomised phase IIa clinical trial (RCT)Bettina Hohberger, Marion Ganslmayer, Thomas Harrer, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Anticancer Research|January 9, 2021
Vimentin 3 Expression in Prostate Cancer CellsBarbara KÖditz, Andreas Stog, Heike GÖbel, et al.
Biomedicines|November 27, 2025
Evaluation of Stereopsis Performance, Gaze Direction and Pupil Diameter in Post-COVID Syndrome Using Machine LearningThomas S Knauer, Christian Y Mardin, Jürgen Rech, et al.
Eclinicalmedicine|July 30, 2025
Safety, tolerability and clinical effects of rovunaptabin, also known as BC007 on fatigue and quality of life in patients with Post-COVID syndrome (reCOVer): a prospective, exploratory, placebo-controlled, double-blind, randomised phase IIa clinical trial (RCT)Bettina Hohberger, Marion Ganslmayer, Thomas Harrer, et al.
Pageof 1